Abstract
The effect of albumin and α1 acid-glycoprotein (AAG) on the binding of cibenzoline was studied using the pH 7.4 phosphate buffer (PBs) and human plasma. The binding in 40 inpatients who received cibenzoline therapy was measured. The cibenzoline concentrations of samples were measured by high performance liquid chromatography. As a result, not only the PBs but also human plasma samples the binding increased in propotion as the concentrations of albumin and AAG increased. On the other hard the binding decreased in inverse proportion as the total cibenzoline concentration increased. However, in the patient samples the effect of the total concentration of cibenzoline and the concentrations of albumin and AAG on the binding was slight and the mean binding ratio was about 80%. These results suggest that when clinically monitoring the cibenzoline blood concentration in clinical monitoring the total concentrations of cibenzoline alone appears to be sufficient.
